{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T15:46:55Z","timestamp":1792511215682,"version":"4.5.0"},"reference-count":58,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T00:00:00Z","timestamp":1788393600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100005026","name":"Fondation contre le Cancer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005026","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cell Reports Medicine"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.xcrm.2026.103080","type":"journal-article","created":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T15:18:07Z","timestamp":1790695087000},"page":"103080","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["A multi-omics analysis of advanced triple-negative breast cancer identifies predictors to chemo-immunotherapy and on-treatment dynamics"],"prefix":"10.1016","volume":"7","author":[{"given":"Nicolaas","family":"Van Renne","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisa","family":"Agostinetto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Joaqu\u00edn Garc\u00eda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie","family":"Morfouace","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcin","family":"Mo\u017cejko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zo\u00eb","family":"Denis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophie","family":"D\u00e9glise","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernd","family":"Bodenmiller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henoch S.","family":"Hong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Venet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcela","family":"Carausu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robin","family":"Liechti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"St\u00e9phanie","family":"Tissot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sylvie","family":"Rusakiewicz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mattia","family":"Rediti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xavier","family":"Catteau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Schulz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Delphine","family":"Loirat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Herrero Saboya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe","family":"Aftimos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matteo","family":"Benelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angel L.","family":"Guerrero-Zotano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Gombos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans","family":"Wildiers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3749-1531","authenticated-orcid":false,"given":"Jip","family":"Van Dinter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ariane","family":"Sickinghe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolas","family":"Penel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Charles","family":"Goeminne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00falio","family":"Oliveira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7097-1131","authenticated-orcid":false,"given":"Birute","family":"Brasiuniene","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emanuela","family":"Romano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4263-5974","authenticated-orcid":false,"given":"Justin M.","family":"Balko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marleen","family":"Kok","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ewa","family":"Szczurek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christos","family":"Sotiriou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3751-0819","authenticated-orcid":false,"given":"Laurence","family":"Buisseret","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.xcrm.2026.103080_bib1","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1016\/j.annonc.2021.09.019","article-title":"ESMO Clinical Practice Guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer","volume":"32","author":"Gennari","year":"2021","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.xcrm.2026.103080_bib2","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1038\/s41523-023-00508-3","article-title":"Immunotherapy in breast cancer: an overview of current strategies and perspectives","volume":"9","author":"Debien","year":"2023","journal-title":"Npj Breast Cancer"},{"key":"10.1016\/j.xcrm.2026.103080_bib3","doi-asserted-by":"crossref","first-page":"953","DOI":"10.3390\/jcm12030953","article-title":"Predictive Biomarkers for Response to Immunotherapy in Triple Negative Breast Cancer: Promises and Challenges","volume":"12","author":"Wang","year":"2023","journal-title":"J. Clin. Med."},{"key":"10.1016\/j.xcrm.2026.103080_bib4","doi-asserted-by":"crossref","first-page":"2750","DOI":"10.1172\/JCI45014","article-title":"Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies","volume":"121","author":"Lehmann","year":"2011","journal-title":"J. Clin. Investig."},{"key":"10.1016\/j.xcrm.2026.103080_bib5","doi-asserted-by":"crossref","first-page":"1688","DOI":"10.1158\/1078-0432.CCR-14-0432","article-title":"Comprehensive genomic analysis identifies novel subtypes and targets of triple-negative breast cancer","volume":"21","author":"Burstein","year":"2015","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.xcrm.2026.103080_bib6","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1093\/annonc\/mdy024","article-title":"Unravelling triple-negative breast cancer molecular heterogeneity using an integrative multiomic analysis","volume":"29","author":"Bareche","year":"2018","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.xcrm.2026.103080_bib7","article-title":"Spatial transcriptomics reveals substantial heterogeneity in triple-negative breast cancer with potential clinical implications","volume":"15","author":"Wang","year":"2024","journal-title":"Nat. Commun."},{"key":"10.1016\/j.xcrm.2026.103080_bib8","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1016\/j.ccell.2019.02.001","article-title":"Genomic and Transcriptomic Landscape of Triple-Negative Breast Cancers: Subtypes and Treatment Strategies","volume":"35","author":"Jiang","year":"2019","journal-title":"Cancer Cell"},{"key":"10.1016\/j.xcrm.2026.103080_bib9","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/S1470-2045(23)00579-X","article-title":"Optimising first-line subtyping-based therapy in triple-negative breast cancer (FUTURE-SUPER): a multi-cohort, randomised, phase 2 trial","volume":"25","author":"Fan","year":"2024","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.xcrm.2026.103080_bib10","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1038\/s41422-023-00795-2","article-title":"Subtyping-based platform guides precision medicine for heavily pretreated metastatic triple-negative breast cancer: The FUTURE phase II umbrella clinical trial","volume":"33","author":"Liu","year":"2023","journal-title":"Cell Res."},{"key":"10.1016\/j.xcrm.2026.103080_bib11","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1200\/JCO.2026.44.16_suppl.1020","article-title":"Impact of bevacizumab on the efficacy of antibody\u2013drug conjugates as later-line treatment of basal-like immune-suppressed triple-negative breast cancer","volume":"44","author":"Liu","year":"2026","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.xcrm.2026.103080_bib12","doi-asserted-by":"crossref","first-page":"7018","DOI":"10.1038\/s41467-023-42744-y","article-title":"Paclitaxel plus carboplatin and durvalumab with or without oleclumab for women with previously untreated locally advanced or metastatic triple-negative breast cancer: the randomized SYNERGY phase I\/II trial","volume":"14","author":"Buisseret","year":"2023","journal-title":"Nat. Commun."},{"key":"10.1016\/j.xcrm.2026.103080_bib13","article-title":"Continuous replenishment of the dysfunctional CD8 T cell axis is associated with response to chemoimmunotherapy in advanced breast cancer","volume":"6","author":"Metoikidou","year":"2025","journal-title":"Cell Rep. Med."},{"key":"10.1016\/j.xcrm.2026.103080_bib14","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1200\/JCO.2025.43.16_suppl.1097","article-title":"First-line durvalumab plus chemotherapy with or without oleclumab for locally advanced or metastatic triple-negative breast cancer: SYNERGY overall survival and circulating tumor DNA analysis","volume":"43","author":"Agostinetto","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.xcrm.2026.103080_bib15","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1056\/NEJMoa0804525","article-title":"Gene expression in fixed tissues and outcome in hepatocellular carcinoma","volume":"359","author":"Hoshida","year":"2008","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.xcrm.2026.103080_bib16","article-title":"A liver gene signature links liver cancer risk in chronic viral hepatitis to intrahepatic IgA plasma cells. JHEP Rep","volume":"8","author":"Van Renne","year":"2026","journal-title":"JHEP Rep."},{"key":"10.1016\/j.xcrm.2026.103080_bib17","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1093\/annonc\/mdx730","article-title":"Clinical significance of CD73 in triple-negative breast cancer: multiplex analysis of a phase III clinical trial","volume":"29","author":"Buisseret","year":"2018","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.xcrm.2026.103080_bib18","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0015543","article-title":"Nearest template prediction: a single-sample-based flexible class prediction with confidence assessment","volume":"5","author":"Hoshida","year":"2010","journal-title":"PLoS One"},{"key":"10.1016\/j.xcrm.2026.103080_bib19","doi-asserted-by":"crossref","first-page":"2055","DOI":"10.1016\/j.humpath.2013.03.010","article-title":"Metastatic triple-negative breast cancers at first relapse have fewer tumor-infiltrating lymphocytes than their matched primary breast tumors: a pilot study","volume":"44","author":"Cimino-Mathews","year":"2013","journal-title":"Hum. Pathol."},{"key":"10.1016\/j.xcrm.2026.103080_bib20","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1038\/s41523-023-00548-9","article-title":"International research to address the challenges of metastatic breast cancer: the AURORA Program (BIG 14-01)","volume":"9","author":"Caballero","year":"2023","journal-title":"NPJ Breast Cancer"},{"key":"10.1016\/j.xcrm.2026.103080_bib21","doi-asserted-by":"crossref","first-page":"2796","DOI":"10.1158\/2159-8290.CD-20-1647","article-title":"Genomic and Transcriptomic Analyses of Breast Cancer Primaries and Matched Metastases in AURORA, the Breast International Group (BIG) Molecular Screening Initiative","volume":"11","author":"Aftimos","year":"2021","journal-title":"Cancer Discov."},{"key":"10.1016\/j.xcrm.2026.103080_bib22","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1038\/s41591-019-0432-4","article-title":"Immune induction strategies in metastatic triple-negative breast cancer to enhance the sensitivity to PD-1 blockade: the TONIC trial","volume":"25","author":"Voorwerk","year":"2019","journal-title":"Nat. Med."},{"key":"10.1016\/j.xcrm.2026.103080_bib23","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1158\/1078-0432.CCR-23-1349","article-title":"Phase II Clinical Trial of Pembrolizumab and Chemotherapy Reveals Distinct Transcriptomic Profiles by Radiologic Response in Metastatic Triple-Negative Breast Cancer","volume":"30","author":"Wilkerson","year":"2024","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.xcrm.2026.103080_bib24","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1001\/jamaoncol.2023.5424","article-title":"Atezolizumab in Combination With Carboplatin and Survival Outcomes in Patients With Metastatic Triple-Negative Breast Cancer: The TBCRC 043 Phase 2 Randomized Clinical Trial","volume":"10","author":"Lehmann","year":"2024","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.xcrm.2026.103080_bib25","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1186\/s13073-015-0131-9","article-title":"The Sweden Cancerome Analysis Network - Breast (SCAN-B) Initiative: a large-scale multicenter infrastructure towards implementation of breast cancer genomic analyses in the clinical routine","volume":"7","author":"Saal","year":"2015","journal-title":"Genome Med."},{"key":"10.1016\/j.xcrm.2026.103080_bib26","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1186\/1471-2105-9-559","article-title":"WGCNA: an R package for weighted correlation network analysis","volume":"9","author":"Langfelder","year":"2008","journal-title":"BMC Bioinf."},{"key":"10.1016\/j.xcrm.2026.103080_bib27","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1038\/nature11412","article-title":"Comprehensive molecular portraits of human breast tumours","volume":"490","year":"2012","journal-title":"Nature"},{"key":"10.1016\/j.xcrm.2026.103080_bib28","article-title":"MultiNicheNet: a flexible framework for differential cell-cell communication analysis from multi-sample multi-condition single-cell transcriptomics data","author":"Browaeys","year":"2023","journal-title":"bioRxiv"},{"key":"10.1016\/j.xcrm.2026.103080_bib29","article-title":"Multi-modal image analysis for large-scale cancer tissue studies within IMMUcan","volume":"5","author":"Eling","year":"2025","journal-title":"Cell Rep. Methods"},{"key":"10.1016\/j.xcrm.2026.103080_bib30","article-title":"Cellohood: multi-granular discovery of cellular neighborhoods with a permutation-invariant set transformer auto-encoder","author":"Mo\u017cejko","year":"2025","journal-title":"bioRxiv"},{"key":"10.1016\/j.xcrm.2026.103080_bib31","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1038\/s41568-024-00728-0","article-title":"Tertiary lymphoid structures in anticancer immunity","volume":"24","author":"Teillaud","year":"2024","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.xcrm.2026.103080_bib32","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1016\/j.ccell.2023.02.015","article-title":"Activated fibroblasts in cancer: Perspectives and challenges","volume":"41","author":"Caligiuri","year":"2023","journal-title":"Cancer Cell"},{"key":"10.1016\/j.xcrm.2026.103080_bib33","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1038\/s41568-019-0144-6","article-title":"Tertiary lymphoid structures in the era of cancer immunotherapy","volume":"19","author":"Saut\u00e8s-Fridman","year":"2019","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.xcrm.2026.103080_bib34","doi-asserted-by":"crossref","DOI":"10.1016\/j.tranon.2024.102140","article-title":"The PIK3CA gene and its pivotal role in tumor tropism of triple-negative breast cancer","volume":"50","author":"Mallick","year":"2024","journal-title":"Transl. Oncol."},{"key":"10.1016\/j.xcrm.2026.103080_bib35","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1093\/annonc\/mdz133","article-title":"Targeting the PI3-kinase pathway in triple-negative breast cancer","volume":"30","author":"Pascual","year":"2019","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.xcrm.2026.103080_bib36","doi-asserted-by":"crossref","first-page":"410","DOI":"10.21037\/atm-21-698","article-title":"PIK3CA mutation confers resistance to chemotherapy in triple-negative breast cancer by inhibiting apoptosis and activating the PI3K\/AKT\/mTOR signaling pathway","volume":"9","author":"Hu","year":"2021","journal-title":"Ann. Transl. Med."},{"key":"10.1016\/j.xcrm.2026.103080_bib37","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2020.1729299","article-title":"PD-L1 is overexpressed on breast cancer stem cells through notch3\/mTOR axis","volume":"9","author":"Mansour","year":"2020","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.xcrm.2026.103080_bib38","doi-asserted-by":"crossref","first-page":"S240","DOI":"10.1016\/j.annonc.2025.08.550","article-title":"116MO PIK3CA helical but not kinase mutations and enrichment of M2 macrophages predict response to taselisib in the LORELEI phase II randomized trial","volume":"36","author":"Collet","year":"2025","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.xcrm.2026.103080_bib39","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1038\/s41586-023-05940-w","article-title":"PI3K\u03b2 controls immune evasion in PTEN-deficient breast tumours","volume":"617","author":"Bergholz","year":"2023","journal-title":"Nature"},{"key":"10.1016\/j.xcrm.2026.103080_bib40","doi-asserted-by":"crossref","first-page":"6340","DOI":"10.1158\/0008-5472.CAN-17-2210","article-title":"Combined CDK4\/6 and PI3K\u03b1 Inhibition Is Synergistic and Immunogenic in Triple-Negative Breast Cancer","volume":"77","author":"Teo","year":"2017","journal-title":"Cancer Res."},{"key":"10.1016\/j.xcrm.2026.103080_bib41","doi-asserted-by":"crossref","first-page":"S360","DOI":"10.1016\/j.annonc.2024.08.295","article-title":"347MO The safety and efficacy of ivonescimab in combination with chemotherapy as first-line (1L) treatment for triple-negative breast cancer (TNBC)","volume":"35","author":"Ouyang","year":"2024","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.xcrm.2026.103080_bib42","article-title":"348MO A phase Ib\/II study to assess the safety and efficacy of PM8002\/BNT327 in combination with nab-paclitaxel for first-line treatment of locally advanced or metastatic triple-negative breast cancer","volume":"35","author":"Wu","year":"2024","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.xcrm.2026.103080_bib43","first-page":"PO2","article-title":"Abstract PO2-06-09: A prospective phase 2 study on efficacy and safety of AK105, anlotinib combined with nab-paclitaxel (nab-P) as a first-line therapy in patients(pts) with advanced triple-negative breast cancer(TNBC)","volume":"84","author":"Zhang","year":"2024","journal-title":"Cancer Res."},{"key":"10.1016\/j.xcrm.2026.103080_bib44","article-title":"The tumor microenvironment (TME) and atezolizumab + nab-paclitaxel (A+nP) activity in metastatic triple-negative","author":"Emens","year":"2021","journal-title":"breast cancer (mTNBC)"},{"key":"10.1016\/j.xcrm.2026.103080_bib45","doi-asserted-by":"crossref","first-page":"2108","DOI":"10.1056\/NEJMoa1809615","article-title":"Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer","volume":"379","author":"Schmid","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.xcrm.2026.103080_bib46","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1056\/NEJMoa2202809","article-title":"Pembrolizumab plus Chemotherapy in Advanced Triple-Negative Breast Cancer","volume":"387","author":"Cortes","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.xcrm.2026.103080_bib47","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1038\/nrclinonc.2010.154","article-title":"Triple-negative breast cancer: disease entity or title of convenience?","volume":"7","author":"Carey","year":"2010","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.xcrm.2026.103080_bib54","doi-asserted-by":"crossref","first-page":"4908","DOI":"10.1158\/1078-0432.CCR-23-1267","article-title":"Differential Benefit of Metronomic Chemotherapy Among Triple-Negative Breast Cancer Subtypes Treated in the IBCSG Trial 22\u201300","volume":"29","author":"Joaquin Garcia","year":"2023","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.xcrm.2026.103080_bib48","doi-asserted-by":"crossref","first-page":"3573","DOI":"10.1016\/j.cell.2021.04.048","article-title":"Integrated analysis of multimodal single-cell data","volume":"184","author":"Hao","year":"2021","journal-title":"Cell"},{"key":"10.1016\/j.xcrm.2026.103080_bib49","doi-asserted-by":"crossref","DOI":"10.7717\/peerj.6222","article-title":"LiBiNorm: an htseq-count analogue with improved normalisation of Smart-seq2 data and library preparation diagnostics","volume":"7","author":"Dyer","year":"2019","journal-title":"PeerJ"},{"key":"10.1016\/j.xcrm.2026.103080_bib58","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1038\/nmeth.4197","article-title":"Salmon provides fast and bias-aware quantification of transcript expression","volume":"14","author":"Patro","year":"2017","journal-title":"Nat Methods"},{"key":"10.1016\/j.xcrm.2026.103080_bib50","doi-asserted-by":"crossref","first-page":"2114","DOI":"10.1093\/bioinformatics\/btu170","article-title":"Trimmomatic: a flexible trimmer for Illumina sequence data","volume":"30","author":"Bolger","year":"2014","journal-title":"Bioinformatics"},{"key":"10.1016\/j.xcrm.2026.103080_bib51","doi-asserted-by":"crossref","first-page":"3565","DOI":"10.1038\/s41596-023-00881-0","article-title":"An end-to-end workflow for multiplexed image processing and analysis","volume":"18","author":"Windhager","year":"2023","journal-title":"Nat. Protoc."},{"key":"10.1016\/j.xcrm.2026.103080_bib52","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1093\/bioinformatics\/bts635","article-title":"STAR: ultrafast universal RNA-seq aligner","volume":"29","author":"Dobin","year":"2013","journal-title":"Bioinformatics"},{"key":"10.1016\/j.xcrm.2026.103080_bib53","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1002\/hep.29203","article-title":"Persisting risk of hepatocellular carcinoma after hepatitis C virus cure monitored by a liver transcriptome signature","volume":"66","author":"Ono","year":"2017","journal-title":"Hepatology"},{"key":"10.1016\/j.xcrm.2026.103080_bib55","doi-asserted-by":"crossref","first-page":"1970","DOI":"10.1038\/s41591-021-01520-5","article-title":"IL-1-driven stromal-neutrophil interactions define a subset of patients with inflammatory bowel disease that does not respond to therapies","volume":"27","author":"Friedrich","year":"2021","journal-title":"Nat. Med."},{"key":"10.1016\/j.xcrm.2026.103080_bib56","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1038\/s41592-019-0619-0","article-title":"Fast, sensitive and accurate integration of single-cell data with Harmony","volume":"16","author":"Korsunsky","year":"2019","journal-title":"Nat. Methods"},{"key":"10.1016\/j.xcrm.2026.103080_bib57","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1038\/s41587-021-01094-0","article-title":"Whole-cell segmentation of tissue images with human-level performance using large-scale data annotation and deep learning","volume":"40","author":"Greenwald","year":"2022","journal-title":"Nat. Biotechnol."}],"container-title":["Cell Reports Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666379126004970?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666379126004970?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T15:09:03Z","timestamp":1792508943000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666379126004970"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":58,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["S2666379126004970"],"URL":"https:\/\/doi.org\/10.1016\/j.xcrm.2026.103080","relation":{},"ISSN":["2666-3791"],"issn-type":[{"value":"2666-3791","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A multi-omics analysis of advanced triple-negative breast cancer identifies predictors to chemo-immunotherapy and on-treatment dynamics","name":"articletitle","label":"Article Title"},{"value":"Cell Reports Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.xcrm.2026.103080","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"103080"}}